ATE260099T1 - Neue hemmern von fortgeschrittenen glykosilierung-endprodukten - Google Patents

Neue hemmern von fortgeschrittenen glykosilierung-endprodukten

Info

Publication number
ATE260099T1
ATE260099T1 AT00920121T AT00920121T ATE260099T1 AT E260099 T1 ATE260099 T1 AT E260099T1 AT 00920121 T AT00920121 T AT 00920121T AT 00920121 T AT00920121 T AT 00920121T AT E260099 T1 ATE260099 T1 AT E260099T1
Authority
AT
Austria
Prior art keywords
proteins
inhibit
glycation
compounds
aging
Prior art date
Application number
AT00920121T
Other languages
English (en)
Inventor
Samuel Rahbar
Iraj Lalezari
Original Assignee
Hope City
Proscience Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hope City, Proscience Corp filed Critical Hope City
Application granted granted Critical
Publication of ATE260099T1 publication Critical patent/ATE260099T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT00920121T 1999-04-05 2000-04-05 Neue hemmern von fortgeschrittenen glykosilierung-endprodukten ATE260099T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12783599P 1999-04-05 1999-04-05
PCT/US2000/008938 WO2000059875A2 (en) 1999-04-05 2000-04-05 Novel inhibitors of formation of advanced glycation endproducts (age's)

Publications (1)

Publication Number Publication Date
ATE260099T1 true ATE260099T1 (de) 2004-03-15

Family

ID=22432212

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920121T ATE260099T1 (de) 1999-04-05 2000-04-05 Neue hemmern von fortgeschrittenen glykosilierung-endprodukten

Country Status (8)

Country Link
US (1) US6337350B1 (de)
EP (1) EP1165064B1 (de)
JP (1) JP5209832B2 (de)
AT (1) ATE260099T1 (de)
AU (1) AU763750B2 (de)
CA (1) CA2368688C (de)
DE (1) DE60008509T2 (de)
WO (1) WO2000059875A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030133B2 (en) * 1999-04-05 2006-04-18 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGEs)
US6605642B2 (en) 1999-04-05 2003-08-12 City Of Hope Inhibitors of formation of advanced glycation endproducts (AGES)
US6589944B1 (en) * 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6787566B2 (en) * 1999-04-05 2004-09-07 City Of Hope Breakers of advanced glycation endproducts
US20030199574A1 (en) 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
DE10158076B4 (de) * 2001-11-27 2005-09-01 Beiersdorf Ag Kosmetische und/oder dermatologische Zubereitungen mit einem Gehalt an Aryl-Ureido-Verbindungen und ihre Verwendung
RU2339369C2 (ru) * 2002-02-13 2008-11-27 Витро-Ретинол Текнолоджиз, Инк. Лечение офтальмологических нарушений с использованием мочевины и ее производных
US20040057949A1 (en) * 2002-09-23 2004-03-25 Depaolis Potito U. Hemodialysis method for improving immune system function
US20040137068A1 (en) * 2002-12-20 2004-07-15 Rajiv Bhushan Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
ATE446951T1 (de) * 2003-06-10 2009-11-15 Biondi Ricardo Miguel Verwendung einer verbingung gemäss formel i zur herstellung einer pharmazeutischen zubereitung
AU2004287434B2 (en) 2003-10-27 2011-04-07 City Of Hope Methods of lowering lipid levels in a mammal
US8829051B2 (en) * 2004-05-24 2014-09-09 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
FR2883873B1 (fr) * 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
CA2615231A1 (en) * 2005-07-15 2007-01-25 Chakshu Research Inc. Prevention and treatment of ophthalmic complications of diabetes
US8048896B2 (en) * 2005-10-05 2011-11-01 Cell Viable Corporation Methods for inhibiting and breaking AGE complex formation
US8053449B2 (en) * 2005-10-05 2011-11-08 Cell Viable Corporation Method for inhibiting AGE complex formation
US8580854B2 (en) * 2005-11-09 2013-11-12 City Of Hope Methods of suppression of rage gene expression and rage triggered inflammatory genes by selected age-inhibitors
DE102007041232A1 (de) 2007-08-30 2009-03-05 Henkel Ag & Co. Kgaa Verwendung von Sulfonylharnstoffen zur Spaltung von AGEs
TW200900072A (en) * 2007-03-22 2009-01-01 Arete Therapeutics Inc Soluble epoxide hydrolase inhibitors
US8124655B2 (en) * 2007-06-15 2012-02-28 City Of Hope Use of LR-90 and LR-102 to overcome insulin resistance
FR2918570B1 (fr) * 2007-07-09 2012-10-05 Engelhard Lyon DIGLYCATION DES AGEs.
DE102007054653A1 (de) 2007-11-14 2009-05-20 Henkel Ag & Co. Kgaa Verwendung von Thioharnstoff-Derivaten zur Spaltung von AGEs
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
EP2261214A1 (de) * 2009-06-12 2010-12-15 Splicos Sas Zusammensetzungen, die zur Behandlung von vorzeitiger Alterung und insbesondere Hutchinson-Gilford-Syndrom von Nutzen sind
CN104844510B (zh) * 2009-06-12 2019-04-23 Abivax公司 用于治疗过早衰老和尤其是早衰的化合物
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
EP2465502A1 (de) 2010-12-15 2012-06-20 Société Splicos Nützliche Verbindungen zur Behandlung von AIDS
US9808434B2 (en) 2011-01-27 2017-11-07 City Of Hope Compound for treating cancer and diabetes
WO2012103523A2 (en) 2011-01-27 2012-08-02 Samuel Rahbar Novel modulators of development of adipocyte and cancer cells
CN102718703B (zh) * 2011-03-31 2016-09-14 中国医学科学院药物研究所 Gk和ppar双重激动活性的含有二甲基的芳基脲类衍生物
CN102718727B (zh) * 2011-03-31 2016-04-20 中国医学科学院药物研究所 Gk和ppar双重激动活性的芳基脲类衍生物
WO2013078446A2 (en) * 2011-11-23 2013-05-30 Fabricant Jill S Derivatives of phenoxyisobutyric acid
EP2757161A1 (de) 2013-01-17 2014-07-23 Splicos miRNA-124 als ein Biomarker für virale Infektion
CN105530938B (zh) 2013-07-05 2019-10-22 Abivax公司 用于治疗由逆转录病毒引起的疾病的化合物
US9827236B2 (en) * 2014-05-11 2017-11-28 Mythri Ambatipudi Method of inhibiting the glycation of nutrient and endogenous proteins and peroxidation of nutrient and endogenous lipids
EP2974729A1 (de) 2014-07-17 2016-01-20 Abivax Chinolinderivate zur Verwendung bei der Behandlung von Entzündungskrankheiten
CN104961645A (zh) * 2015-07-22 2015-10-07 中国药科大学 苯氧乙酸类衍生物、其制备方法及其作为药物的用途
WO2019055490A1 (en) 2017-09-14 2019-03-21 The Board Of Trustees Of The Leland Stanford Junior University PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION
JP2019214546A (ja) * 2018-06-11 2019-12-19 学校法人福岡大学 終末糖化産物生成抑制剤及び医薬組成物
EP3669873A1 (de) 2018-12-20 2020-06-24 Abivax Chinolinderivate zur verwendung bei der behandlung von entzündlichen krankheiten

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272176A (en) * 1984-03-19 1993-12-21 The Rockefeller University Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
DE3410927A1 (de) * 1984-03-24 1985-10-03 Hoechst Ag, 6230 Frankfurt Vollaromatische polyester, verfahren zu ihrer herstellung und entsprechende formkoerper
JPS619227A (ja) * 1984-06-22 1986-01-16 生体機能利用化学品新製造技術研究組合 キンポウゲ科植物の組織培養方法
JPS6222517A (ja) * 1985-07-23 1987-01-30 株式会社ツムラ ウリ科植物不定根の培養方法
JPS6232880A (ja) * 1985-08-06 1987-02-12 Seitai Kinou Riyou Kagakuhin Shinseizou Gijutsu Kenkyu Kumiai キンポウゲ科植物の組織培養方法
US5268500A (en) 1987-06-15 1993-12-07 Montefiore Medical Center Compound, composition and method for the reduction of lipids the modification of the affinity of hemoblogin for oxygen and the prevention of platelet aggregation
US4921997A (en) 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5093367A (en) 1988-06-15 1992-03-03 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
US5677330A (en) * 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
WO1995031192A1 (en) * 1994-05-16 1995-11-23 Thomas Jefferson University Method and use of agents to inhibit protein polymerization and methods of identifying these agents
US5962651A (en) * 1995-01-27 1999-10-05 Montefiore Medical Center Modified hemoglobin and its use as a component of an artificial blood substitute
US5602277A (en) * 1995-03-30 1997-02-11 Biocryst Pharmaceuticals, Inc. Substituted benzene derivatives useful as neuraminidase inhibitors
US5716987A (en) 1996-06-21 1998-02-10 Bristol-Myers Squibb Company Prophylactic and therapeutic treatment of skin sensitization and irritation

Also Published As

Publication number Publication date
JP5209832B2 (ja) 2013-06-12
JP2002541139A (ja) 2002-12-03
WO2000059875A2 (en) 2000-10-12
US6337350B1 (en) 2002-01-08
DE60008509T2 (de) 2004-12-16
EP1165064B1 (de) 2004-02-25
AU763750B2 (en) 2003-07-31
WO2000059875A3 (en) 2001-03-29
EP1165064A2 (de) 2002-01-02
CA2368688A1 (en) 2000-10-12
CA2368688C (en) 2009-08-11
DE60008509D1 (de) 2004-04-01
AU4070700A (en) 2000-10-23

Similar Documents

Publication Publication Date Title
ATE260099T1 (de) Neue hemmern von fortgeschrittenen glykosilierung-endprodukten
DE60219894D1 (de) Neue inhibitoren der bildung der fortgeschrittenen glykosylierungsendprodukte
WO2000066102A3 (en) Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age&#39;s)
ATE388704T1 (de) Umkehrung der fortgeschrittenen glycosylierungsvernetzungen durch verwendung von heterozyklisch substituierten thiazoliumsalzen
ATE245420T1 (de) Verwendung von thiazoliumverbindungen zum verhindern und umkehren der bildung von endprodukten der fortgeschrittenen glykosylierung
EP0316852A3 (de) Hemmer von nichtenzymatischer Quervernetzung
ATE112165T1 (de) Verfahren und mittel zur hemmung des proteinveraltens.
Jedziniak et al. Activators and inhibitors of lens aldose reductase
ES2127965T3 (es) Derivados de acidos benzofuranil- y benzotiofenil-alcanocarboxilicos heterociclilcarbonil sustituidos.
WO1994029287A1 (de) Aryliden-4-oxo-2-thioxo-3-thiazolidincarbonsäuren, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ES2174132T3 (es) N-acil-a,omp-alquil-hidrazino-carboximidamidas.
WO2004071416A3 (en) Novel inhibitors of formation of advanced glycation endproducts (ages)
NO903325D0 (no) Ensileringssammensetning.
US2491646A (en) Process for treating animal materials
Wang et al. Kinetics of the course of inactivation of aminoacylase by 1, 10-phenanthroline
HUNDT et al. On the molecular weight of mitochondrially synthesized subunits of rat liver cytochrome oxidase
WO1996021450A3 (en) Bis-[hydrazones]
ATE223384T1 (de) Substituierte imidazoliunsalze und deren verwendung zur hemmung der proteinalterung
US2433879A (en) Manufacture of amino acid preparations intended for intravenous supply of nutrients
SU1555365A1 (ru) Способ гидролиза растительного сырь
浜井昌志 et al. Stabilization of fish myosin subfragment-1 by adenosine 5'-triphosphate and by sorbitol.
Hidalgo et al. Antioxidative Activity of Non-Enzymatically Browned Proteins by
NO953569L (no) Bisyklisk oksazol- og tiazol substituerte etere, fremgangsmåte for deres fremstilling og farmasöytisk preparat inneholdende disse
Li et al. The role of glycation and autoxidation on crystallin aggregation
Denborough et al. Failure of phenol to remove residual protein from hyaluronic acid

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties